State-of-the-Art Clinical Studies on Synapsa
On-going Synapsa Studies
- 7 ‘foundational’ clinical trials
- 6 ’targeted’ randomized, double-blind,
placebo-controlled clinical trials
- Additional clinical trials underway and planned
- Synapsa has been shown to be safe, well tolerated and devoid of undesirable side effects in clinical studies
Stough, 2001 showed a statistically significant improvement in speed of visual information processing, learning rate and memory consolidation in subjects 18-60 years of age consuming 300 mg/day Synapsa. A statistically significant reduction in the rate of forgetting was also observed.
Roodenrys, 2002 conducted a randomized, double-blind, placebo-controlled 12-week trial that demonstrated a significant effect of Synapsa (300mg/d) on the retention of new information by participants 40-65 years of age.
Stough, 2008 conducted a randomized double-blind, placebo-controlled 90-day study with 62 participants, ages 18-60, consuming 300 mg/day. Synapsa showed a statistically significant improvement in working memory, visual information processing (sustained attention) and accuracy in complex cognitive tasks.
Downey, 2012 studied two different doses (320 mg/640 mg) in a study on sustained cognitive performance, examining the acute (short term) effect of Synapsa in healthy adult subjects. Significantly improved performance was seen in faster information processing and improved decision making time in a multitasking environment.
PLT Health Solutions is committed to an on-going program of clinical study for Synapsa – with more support for the target market, as well as new indications. Additional information on these studies and more are available.
Chronic and Acute Effects of Synapsa